The medical community is excited with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s exhibiting significant efficacy in clinical trials for treating obesity. Unlike some existing weight loss treatments, retatrutide appears to offer a greater substantial decrease in body size and improve metabolic health, particular